Clinical trial

Alendronate to Prevent Loss of Bronchoprotection in Asthma

NCT02230332

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-01-01

PhasePHASE2 / PHASE3

Study timeline

Study start (unknown)2015-01-01Date precision: month

Registry last updated2018-01-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Asthmaunresolved

Interventions

AlendronateDRUG · verified · RxNorm: alendronate

PlaceboDRUG

Sponsors & collaborators

Milton S. Hershey Medical Centerlead sponsor

National Heart, Lung, and Blood Institute (NHLBI)collaborator

Mapped research locations

ChicagoIllinois, United States3 BostonMassachusetts, United States1 St LouisMissouri, United States1 San FranciscoCalifornia, United States1 DenverColorado, United States1 TucsonArizona, United States1 Winston-SalemNorth Carolina, United States1 MadisonWisconsin, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02230332 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.